Sex Drugs for Women

Celebrities and Sex Drug Promotions: Why Is This a Problem?

By Olivia Snavely | Apr 13, 2020 | Comments Off on Celebrities and Sex Drug Promotions: Why Is This a Problem?

Celebrity promotions are nothing new – we see them constantly, from athletes endorsing sports equipment to singers promoting skin care brands.

Vyleesi: Another Attempt to Profit from Women’s Health 

By NWHN Staff | Dec 23, 2019 | Comments Off on Vyleesi: Another Attempt to Profit from Women’s Health 

In June, the Food and Drug Administration (FDA) approved bremelanotide (brand name Vyleesi) to treat a lack of sexual desire in premenopausal women.1 The NWHN advocated against the drug’s approval, and spoke in opposition when the approval announcement was made. Here’s why.  

How to Increase Sexual Desire After a Partial Hysterectomy

By NWHN Staff | Sep 18, 2019 | Comments Off on How to Increase Sexual Desire After a Partial Hysterectomy

If you are experiencing low sexual desire, some alternative methods may work better without Addyi’s harmful side effects.

Consumer Health Info: Vyleesi

By NWHN Staff | Jul 12, 2019 | Comments Off on Consumer Health Info: Vyleesi

Bremelanotide (brand name: Vyleesi) is a drug approved by the FDA to treat a lack of sexual desire (hypoactive sexual desire disorder) in premenopausal women.

The NWHN’s Statement on the FDA’s Approval of Vyleesi

By Cindy Pearson | Jun 21, 2019 | Comments Off on The NWHN’s Statement on the FDA’s Approval of Vyleesi

FOR IMMEDIATE RELEASE Contact: Evita Almassi, ealmassi@nwhn.org or 425-749-1886

The NWHN’s Statement on the FDA Ordering Sprout Pharmaceuticals to Retain Black Box Label Warning Women Not Mix Addyi and Alcohol

By Cindy Pearson | Apr 12, 2019 | Comments Off on The NWHN’s Statement on the FDA Ordering Sprout Pharmaceuticals to Retain Black Box Label Warning Women Not Mix Addyi and Alcohol

FOR IMMEDIATE RELEASE Contact: Evita Almassi, ealmassi@nwhn.org
or (202) 682-6240

The NWHN Advises Women to Be Cautious About Using Flibanserin Until New Studies Are Fully Vetted

By Cindy Pearson | Mar 26, 2019 | Comments Off on The NWHN Advises Women to Be Cautious About Using Flibanserin Until New Studies Are Fully Vetted

FOR IMMEDIATE RELEASE Contact: Evita Almassi, ealmassi@nwhn.org

Keep Passing on the Pink Pill: DON’T “Get Addyi Now”!

By NWHN Staff | Jan 24, 2019 | Comments Off on Keep Passing on the Pink Pill: DON’T “Get Addyi Now”!

What do you do when your product isn’t popular and sales have slumped? Gin up an advertising campaign to convince consumers that they absolutely have to have what you’re selling.

Consumer Health Info: Addyi Health

By NWHN Staff | Jul 30, 2018 | Comments Off on Consumer Health Info: Addyi Health

Flibanserin (brand name: Addyi) is the first drug approved by the U.S. Food and Drug Administration (FDA) to treat lack of sexual desire (Hypoactive Sexual Desire Disorder) in premenopausal women.

How Can I Get an Addyi Prescription if My Insurance Does Not Cover It?

By NWHN Staff | Jun 28, 2018 | Comments Off on How Can I Get an Addyi Prescription if My Insurance Does Not Cover It?

“My doctor prescribed me Addyi for HSDD. I cannot afford it and my insurance does not cover it. Are there any other resources to get this medication?”